Novel system to protect against stroke via direct carotid access and robust blood flow reversal initiates a new era in carotid revascularization
SUNNYVALE, Calif., Feb. 10, 2015 /PRNewswire/ -- Silk Road Medical, Inc., a pioneer in the development of transcarotid therapies for intra and extracranial vascular diseases, announces the company has received Food & Drug Administration (FDA) 510(k) clearance for its ENROUTE Transcarotid Neuroprotection System (NPS). The ENROUTE Transcarotid NPS is a first in class system used to directly access the common carotid artery and initiate high rate temporary blood flow reversal to protect the brain from stroke while performing carotid angioplasty and stenting (CAS).
Read More: http://www.prnewswire.com/news-releases/silk-road-medical-announces-fda-510k-clearance-of-the-enroute-transcarotid-neuroprotection-system-300033527.html
Silk Road Medical Announces FDA 510(k) Clearance of the ENROUTE® Transcarotid Neuroprotection System
Via: PR Newswire
Direct access stenting of the carotid artery shows promising results, especially for patients with difficult anatomy at high-risk for both surgery and transfemoral carotid artery stenting (CAS), according to data presented February 3, 2015, at the International Symposium on Endovascular Therapy in Hollywood, FL.
OncoMed Initiates Dosing in Phase 2 Clinical Trial of Demcizumab for the Treatment of Non-Small Cell Lung Cancer
REDWOOD CITY, Calif., Feb. 4, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced that patient dosing has begun in the double-blinded, placebo-controlled, randomized Phase 2 clinical trial of demcizumab (anti-DLL4, OMP-21M18) for the treatment of patients with first-line advanced-stage non-small cell lung cancer (NSCLC).